Figure 1.
Biliary tract cancers (BTCs) are a heterogeneous group of malignancies.
5-FU, 5-fluorouracil; eCCA, extrahepatic cholangiocarcinoma; FOLFOX, 5-fluorouracil and oxaliplatin; FOLFIRI, 5-fluorouracil and irinotecan; iCCA, intrahepatic cholangiocarcinoma; nal-IRI, nanoliposomal irinotecan; PEI, pancreatic exocrine insufficiency. Adapted from Lamarca A, Frizziero M, McNamara MG, Valle JW. Clinical and translational research challenges in biliary tract cancers. Curr Med Chem. 2020;27(29):4756-4777.